Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials
出版年份 2014 全文链接
标题
Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials
作者
关键词
-
出版物
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 39, Issue 10, Pages 1161-1168
出版商
Wiley
发表日期
2014-04-04
DOI
10.1111/apt.12735
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rifaximin in the treatment of recurrentClostridium difficileinfection
- (2012) E. Mattila et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months
- (2012) P. Meyrat et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome
- (2012) Eric Shah et al. AMERICAN JOURNAL OF MEDICINE
- Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg- -Naphthylamide-Inhibitable Efflux Pumps
- (2012) V. Kothary et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VivoSelection of Rifamycin-Resistant Clostridium difficile during Rifaximin Therapy
- (2012) Robert J. Carman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Current State of Clostridium difficile Treatment Options
- (2012) A. A. Venugopal et al. CLINICAL INFECTIOUS DISEASES
- Current Status of Clostridium difficile Infection Epidemiology
- (2012) F. C. Lessa et al. CLINICAL INFECTIOUS DISEASES
- 645 RATES OF COMMONLY OCCURING INFECTIONS IN CIRRHOSIS PATIENTS REMAIN STABLE DURING LONG-TERM RIFAXIMIN TREATMENT
- (2012) A. Sanyal et al. JOURNAL OF HEPATOLOGY
- The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
- (2011) Stacy B Menees et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease
- (2011) Cosimo Prantera et al. GASTROENTEROLOGY
- A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection
- (2011) K. W. Garey et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antibiotic Therapy for the Irritable Bowel Syndrome
- (2011) Jan Tack NEW ENGLAND JOURNAL OF MEDICINE
- Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
- (2011) Mark Pimentel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rifaximin Is Effective for the Treatment ofClostridium difficile—Associated Diarrhea: Results of an Open-Label Pilot Study
- (2011) David T. Rubin et al. Gastroenterology Research and Practice
- Clostridium difficileinfection: update on emerging antibiotic treatment options and antibiotic resistance
- (2010) Dhara Shah et al. Expert Review of Anti-Infective Therapy
- Rifaximin Treatment in Hepatic Encephalopathy
- (2010) Nathan M. Bass et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial
- (2010) P. Patrick Basu et al. Therapeutic Advances in Gastroenterology
- Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with Rifaximin
- (2009) Sergio Peralta et al. WORLD JOURNAL OF GASTROENTEROLOGY
- T1390 Rifaximin for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained Response
- (2008) Anthony Lembo et al. GASTROENTEROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now